scholarly journals Chronic Autoimmune Epithelitis in Sjögren’s Syndrome and Primary Biliary Cholangitis: A Comprehensive Review

2017 ◽  
Vol 4 (2) ◽  
pp. 263-279 ◽  
Author(s):  
Carlo Selmi ◽  
M. Eric Gershwin
Keyword(s):  
Sjögren’S Syndrome ◽  
Sjögren's Syndrome ◽  
Sjogren’S Syndrome ◽  
Sjogren's Syndrome ◽  
Primary Biliary Cholangitis ◽  
Comprehensive Review ◽  
Sjögren‘S Syndrome

scholarly journals Epigenetic Modifications in Generalized Autoimmune Epithelitis: Sjögren’s Syndrome and Primary Biliary Cholangitis

Epigenomes ◽  
2019 ◽  
Vol 3 (3) ◽  
pp. 15
Author(s):  
Pinelopi Arvaniti ◽  
Kalliopi Zachou ◽  
Aggeliki Lyberopoulou ◽  
Nikolaos K. Gatselis ◽  
Wesley H. Brooks ◽  
...  
Keyword(s):  
Epithelial Cells ◽  
Sjögren’S Syndrome ◽  
Sjögren's Syndrome ◽  
Sjogren’S Syndrome ◽  
Sjogren's Syndrome ◽  
Primary Biliary Cholangitis ◽  
Epigenetic Changes ◽  
Disease Pathogenesis ◽  
Immune Mediated ◽  
Sjögren‘S Syndrome

Sjögren’s syndrome (SjS) and primary biliary cholangitis (PBC) can be classified as a model of generalized autoimmune epithelitis based on their frequent coexistence in clinical practice and the highly specific immune mediated injury of target epithelial cells. Both of these autoimmune diseases are characterized by female predominance, highly specific circulating autoantibodies, and immune-mediated destruction of the salivary and lachrymal glands and the biliary epithelial cells, respectively. Although the genetic predisposition has been well described for both diseases, genetic studies have failed to completely elucidate their pathogenesis. The recent integration of epigenetic data, analyzing the different cellular partners, opens new perspectives and allows for better understanding of these complex and still incurable diseases. Epigenetic studies on SjS have elucidated the role of DNA methylation alterations in disease pathogenesis, while epigenetic changes that influence expression of genes on the X chromosome have been implicated in the geo-variability and occurrence of PBC. The aim of this review is to describe the advances in epigenetics in the field of autoimmune epithelitis as well as to highlight how epigenetic changes could contribute to better understanding of disease pathogenesis and progression. These advances could yield insights on novel therapeutic interventions.

Sjögren's syndrome and the epithelial target: A comprehensive review

2013 ◽  
Vol 42 ◽  
pp. 7-18 ◽  
Author(s):  
M.J. Barrera ◽  
V. Bahamondes ◽  
D. Sepúlveda ◽  
A.F.G. Quest ◽  
I. Castro ◽  
...  
Keyword(s):  
Sjögren’S Syndrome ◽  
Sjögren's Syndrome ◽  
Sjogren’S Syndrome ◽  
Sjogren's Syndrome ◽  
Comprehensive Review ◽  
Sjögren‘S Syndrome

Outcome measures for primary Sjögren's syndrome: A comprehensive review

2014 ◽  
Vol 51 ◽  
pp. 51-56 ◽  
Author(s):  
Raphaèle Seror ◽  
Elke Theander ◽  
Hendrika Bootsma ◽  
Simon J. Bowman ◽  
Athanasios Tzioufas ◽  
...  
Keyword(s):  
Sjögren’S Syndrome ◽  
Outcome Measures ◽  
Sjögren's Syndrome ◽  
Sjogren’S Syndrome ◽  
Sjogren's Syndrome ◽  
Primary Sjögren’S Syndrome ◽  
Primary Sjogren’S Syndrome ◽  
Comprehensive Review ◽  
Primary Sjögren's Syndrome ◽  
Sjögren‘S Syndrome

scholarly journals THU0045 IDENTIFICATION OF NOVEL CENTROMERE AUTOANTIGENS IN SJÖGREN’S SYNDROME, SYSTEMIC SCLEROSIS AND PRIMARY BILIARY CHOLANGITIS.

2020 ◽  
Vol 79 (Suppl 1) ◽  
pp. 235.2-235
Author(s):  
N. Kajio ◽  
M. Takeshita ◽  
K. Suzuki ◽  
T. Takeuchi
Keyword(s):  
Systemic Sclerosis ◽  
Sjögren’S Syndrome ◽  
Sjögren's Syndrome ◽  
Sjogren’S Syndrome ◽  
Sjogren's Syndrome ◽  
Primary Biliary Cholangitis ◽  
Chugai Pharmaceutical ◽  
Centromere Protein ◽  
Centromere Proteins ◽  
Sjögren‘S Syndrome

Background:Anti-centromere antibodies (ACA) are detected in the serum of patients with various autoimmune diseases including Sjögren’s syndrome (SjS), systemic sclerosis (SSc) and primary biliary cholangitis (PBC). ACA positivity is correlated with clinical manifestations such as Raynaud’s phenomenon and sclerodactyly and these features are commonly seen across diseases. Although CENPB is thought to be the major antigen against ACA, autoimmune features of other centromere proteins have not been fully evaluated.Objectives:The aim of this study is to elucidate centromere autoantigens comprehensively and clarify their association with pathogenesis of SjS, SSc and PBC.Methods:A centromere protein library was created by cloning 6 single proteins and 10 complexes consisting of 35 proteins belonging to human centromere region. The centromere antigens were immobilized on beads and incubated in the serum of patients with SjS (n = 86), SSc (n = 35), PBC (n = 10), patients with two or more diseases above (n = 44), and healthy volunteers (n = 68). Autoantibodies to each centromere protein were analyzed by flow cytometry.Results:Patients had a wide variety of antibodies against most of centromere antigens including 4 newly identified autoantigens. The hierarchical clustering of each antigen distinguished 2 antigen clusters. The reactivity of autoantibodies against a centromere protein of one cluster was mutually correlated regardless of disease types, indicating that these proteins/protein complexes might be the target of ACA. In addition, our method enabled us to detect sera reacted against multiple centromere antigens in some of the ACA-negative patients with existing methods.Conclusion:We identified 4 novel centromere autoantigens and our data suggested that the main target of ACA was the protein complex rather than a single specific antigen in SjS, SSc and PBC patients. Using the combination of centromere proteins may be useful to detect ACA with higher sensitivity.References:[1]Fritzler MJ, Rattner JB, Luft LM, Edworthy SM, Casiano CA, Peebles C, Mahler M. Historical perspectives on the discovery and elucidation of autoantibodies to centromere proteins (CENP) and the emerging importance of antibodies to CENP-F. Autoimmun Rev. 2011;10:194-200.Disclosure of Interests:Nobuhiko Kajio: None declared, Masaru Takeshita: None declared, Katsuya Suzuki: None declared, Tsutomu Takeuchi Grant/research support from: Eisai Co., Ltd, Astellas Pharma Inc., AbbVie GK, Asahi Kasei Pharma Corporation, Nippon Kayaku Co., Ltd, Takeda Pharmaceutical Company Ltd, UCB Pharma, Shionogi & Co., Ltd., Mitsubishi-Tanabe Pharma Corp., Daiichi Sankyo Co., Ltd., Chugai Pharmaceutical Co. Ltd., Consultant of: Chugai Pharmaceutical Co Ltd, Astellas Pharma Inc., Eli Lilly Japan KK, Speakers bureau: AbbVie GK, Eisai Co., Ltd, Mitsubishi-Tanabe Pharma Corporation, Chugai Pharmaceutical Co Ltd, Bristol-Myers Squibb Company, AYUMI Pharmaceutical Corp., Eisai Co., Ltd, Daiichi Sankyo Co., Ltd., Gilead Sciences, Inc., Novartis Pharma K.K., Pfizer Japan Inc., Sanofi K.K., Dainippon Sumitomo Co., Ltd.

Infection and autoimmunity in Sjogren's syndrome: A clinical study and comprehensive review

2014 ◽  
Vol 51 ◽  
pp. 17-22 ◽  
Author(s):  
Shaye Kivity ◽  
Maria Teresa Arango ◽  
Michael Ehrenfeld ◽  
Omer Tehori ◽  
Yehuda Shoenfeld ◽  
...  
Keyword(s):  
Clinical Study ◽  
Sjögren’S Syndrome ◽  
Sjögren's Syndrome ◽  
Sjogren’S Syndrome ◽  
Sjogren's Syndrome ◽  
Comprehensive Review ◽  
Sjögren‘S Syndrome

Novel autoantibodies in Sjögren's syndrome: A comprehensive review

2019 ◽  
Vol 18 (2) ◽  
pp. 192-198 ◽  
Author(s):  
Eduardo Martín-Nares ◽  
Gabriela Hernández-Molina
Keyword(s):  
Sjögren’S Syndrome ◽  
Sjögren's Syndrome ◽  
Sjogren’S Syndrome ◽  
Sjogren's Syndrome ◽  
Comprehensive Review ◽  
Sjögren‘S Syndrome
Sign in / Sign up

Export Citation Format

Share Document